Chugai Pharmaceutical Co., Ltd. (CHGCF)
USD 43.95
(44.76%)
USD 43.95
(44.76%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 306.96 Billion JPY | -31.08% |
| 2022 | 445.37 Billion JPY | 27.0% |
| 2021 | 350.67 Billion JPY | 37.25% |
| 2020 | 255.49 Billion JPY | 24.67% |
| 2019 | 204.93 Billion JPY | 25.71% |
| 2018 | 163.02 Billion JPY | 2.16% |
| 2017 | 159.57 Billion JPY | -0.13% |
| 2016 | 159.78 Billion JPY | -0.21% |
| 2015 | 160.13 Billion JPY | 12.94% |
| 2014 | 141.78 Billion JPY | 14.33% |
| 2013 | 124 Billion JPY | 27.0% |
| 2012 | 97.64 Billion JPY | 31.23% |
| 2011 | 74.41 Billion JPY | 26.93% |
| 2010 | 58.62 Billion JPY | -44.62% |
| 2009 | 105.86 Billion JPY | 29.97% |
| 2008 | 81.45 Billion JPY | 11.36% |
| 2007 | 73.14 Billion JPY | 3.72% |
| 2006 | 70.52 Billion JPY | -18.42% |
| 2005 | 86.44 Billion JPY | -3.03% |
| 2004 | 89.14 Billion JPY | -17.14% |
| 2003 | 107.57 Billion JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 308.47 Billion JPY | 20.63% |
| 2024 Q1 | 255.71 Billion JPY | -16.7% |
| 2023 Q1 | 335.05 Billion JPY | -24.77% |
| 2023 Q3 | 282.65 Billion JPY | -11.19% |
| 2023 Q2 | 318.26 Billion JPY | -5.01% |
| 2023 FY | 306.96 Billion JPY | -31.08% |
| 2023 Q4 | 306.96 Billion JPY | 8.6% |
| 2022 Q3 | 392.19 Billion JPY | 23.23% |
| 2022 Q4 | 445.37 Billion JPY | 13.56% |
| 2022 Q2 | 318.26 Billion JPY | -7.6% |
| 2022 Q1 | 344.43 Billion JPY | -1.78% |
| 2022 FY | 445.37 Billion JPY | 27.0% |
| 2021 FY | 350.67 Billion JPY | 37.25% |
| 2021 Q1 | 162.01 Billion JPY | -36.59% |
| 2021 Q2 | 223.7 Billion JPY | 38.08% |
| 2021 Q3 | 262.71 Billion JPY | 17.44% |
| 2021 Q4 | 350.67 Billion JPY | 33.48% |
| 2020 Q2 | 166.2 Billion JPY | -13.2% |
| 2020 Q1 | 191.48 Billion JPY | -6.56% |
| 2020 Q3 | 210.83 Billion JPY | 26.86% |
| 2020 FY | 255.49 Billion JPY | 24.67% |
| 2020 Q4 | 255.49 Billion JPY | 21.18% |
| 2019 Q1 | 171.77 Billion JPY | 5.37% |
| 2019 FY | 204.93 Billion JPY | 25.71% |
| 2019 Q2 | 194.45 Billion JPY | 13.2% |
| 2019 Q4 | 204.93 Billion JPY | -3.43% |
| 2019 Q3 | 212.2 Billion JPY | 9.13% |
| 2018 Q3 | 151.19 Billion JPY | 6.71% |
| 2018 Q4 | 163.02 Billion JPY | 7.82% |
| 2018 Q1 | 141.54 Billion JPY | -11.3% |
| 2018 FY | 163.02 Billion JPY | 2.16% |
| 2018 Q2 | 141.68 Billion JPY | 0.1% |
| 2017 Q4 | 159.57 Billion JPY | 11.29% |
| 2017 Q2 | 153.52 Billion JPY | 2.07% |
| 2017 Q1 | 150.4 Billion JPY | -5.87% |
| 2017 FY | 159.57 Billion JPY | -0.13% |
| 2017 Q3 | 143.38 Billion JPY | -6.6% |
| 2016 Q4 | 159.78 Billion JPY | 15.24% |
| 2016 FY | 159.78 Billion JPY | -0.21% |
| 2016 Q1 | 142.66 Billion JPY | -10.91% |
| 2016 Q3 | 138.65 Billion JPY | 0.86% |
| 2016 Q2 | 137.48 Billion JPY | -3.63% |
| 2015 Q4 | 160.13 Billion JPY | 15.68% |
| 2015 Q3 | 138.42 Billion JPY | 5.77% |
| 2015 Q2 | 130.87 Billion JPY | -1.09% |
| 2015 FY | 160.13 Billion JPY | 12.94% |
| 2015 Q1 | 132.31 Billion JPY | -6.68% |
| 2014 FY | 141.78 Billion JPY | 14.33% |
| 2014 Q1 | 124.2 Billion JPY | 0.16% |
| 2014 Q4 | 141.78 Billion JPY | 8.9% |
| 2014 Q3 | 130.19 Billion JPY | 6.06% |
| 2014 Q2 | 122.75 Billion JPY | -1.16% |
| 2013 Q3 | 119.69 Billion JPY | 13.24% |
| 2013 Q4 | 124 Billion JPY | 3.6% |
| 2013 Q2 | 105.7 Billion JPY | 3.54% |
| 2013 FY | 124 Billion JPY | 27.0% |
| 2013 Q1 | 102.08 Billion JPY | 4.55% |
| 2012 FY | 97.64 Billion JPY | 31.23% |
| 2012 Q1 | 71.71 Billion JPY | -3.62% |
| 2012 Q2 | 72.79 Billion JPY | 1.51% |
| 2012 Q3 | 76.38 Billion JPY | 4.93% |
| 2012 Q4 | 97.64 Billion JPY | 27.83% |
| 2011 FY | 74.41 Billion JPY | 26.93% |
| 2011 Q4 | 74.41 Billion JPY | -10.1% |
| 2011 Q2 | 74.09 Billion JPY | -4.1% |
| 2011 Q1 | 77.25 Billion JPY | 31.79% |
| 2011 Q3 | 82.77 Billion JPY | 11.71% |
| 2010 Q3 | 64.42 Billion JPY | -12.1% |
| 2010 Q4 | 58.62 Billion JPY | -9.01% |
| 2010 FY | 58.62 Billion JPY | -44.62% |
| 2010 Q2 | 73.29 Billion JPY | -11.46% |
| 2010 Q1 | 82.77 Billion JPY | -21.81% |
| 2009 Q4 | 105.86 Billion JPY | 21.84% |
| 2009 Q3 | 86.88 Billion JPY | 1.32% |
| 2009 Q2 | 85.75 Billion JPY | 9.39% |
| 2009 Q1 | 78.38 Billion JPY | 0.0% |
| 2009 FY | 105.86 Billion JPY | 29.97% |
| 2008 FY | 81.45 Billion JPY | 11.36% |
| 2007 FY | 73.14 Billion JPY | 3.72% |
| 2006 FY | 70.52 Billion JPY | -18.42% |
| 2005 FY | 86.44 Billion JPY | -3.03% |
| 2004 FY | 89.14 Billion JPY | -17.14% |
| 2003 FY | 107.57 Billion JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AstraZeneca PLC | 61.86 Billion USD | -396.183% |
| Bristol-Myers Squibb Company PFD CONV 2 | 65.67 Billion USD | -367.409% |
| CSPC Pharmaceutical Group Limited | 1.53 Billion USD | -19835.27% |
| Clarus Therapeutics Holdings, Inc. | 67.62 Million USD | -453810.42% |
| Novartis AG | 53.19 Billion USD | -477.058% |
| PT Kalbe Farma Tbk. | 255.94 Million USD | -119836.469% |